NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
PR Newswire
NEW YORK, Aug. 5, 2026
NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Ashley Mastronardi delivers the pre-market update on August 5th
- The Dow Jones Industrial Average and S&P 500 will look to build off fresh records on hopes of a deal in the Middle East.
- The Dow surpassed 54,000 for the first time ever.
- The S&P 500 clinched its first-ever close above 7,700.
- Expedition Therapeutics Founder & CEO Yi Larson will join NYSE Live following her firm's latest funding round.
- The company says the first patients have been dosed in its Phase 2 clinical trial for EXPD-101, a next-gen treatment for COPD.
- Zeta Global (NYSE: ZETA) CEO David Steinberg will join NYSE Live to deliver the biggest takeaways from the company's Q2 earnings report.
- The firm says it posted its 20th straight 'beat-and-raise' quarter and achieved the 'Rule of 64.'
Opening Bell
AB InBev (NYSE: BUD) rings the NYSE Opening Bell
Closing Bell
Blend (NYSE: BLND) celebrates its 5th anniversary of listing
For market insights, IPO activity, and today's opening bell, download the NYSE TV App: TV.NYSE.com
SOURCE New York Stock Exchange
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States